PF447 IOVANCE PERIPHERAL BLOOD LYMPHOCYTES (PBL): A POTENTIAL CELL THERAPY STRATEGY FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
Lavakumar Karyampudi(Mayo Clinic), Maria Fardis(Pharmacyclics (United States)), Amanda Stramer(Theravance Biopharma (United States)), Noha Gerges(Theravance Biopharma (United States)), Ian Frank(Norwegian Womens Public Health Association), Arvind Natarajan(Sri Devaraj Urs Medical College), Mark A. T. Blaskovich(The University of Queensland), John C. Byrd(University of Cincinnati), Meixiao Long(The Ohio State University), Cécile Chartier(Io Therapeutics (United States))
Cited by 0
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k
Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia
|The Journal of Experimental Medicine|2001|1.1k